We leverage AI to interpret the visible and hidden signals within ECGs, transforming them into a more powerful diagnostic and broad biomarker that improves outcomes and saves lives.

Our FDA-cleared flagship application, AccurECG streamlines interpretation of ECGs.

Extending the use of ECGs towards the detection and management of conditions far beyond its traditional capabilities.

The AccurECG™, AK-AVS™, and AK+ Guard™ are registered trademarks of AccurKardia, Inc., with all intellectual property rights owned by AccurKardia, Inc.

For detailed technical AccurECG requirements, relevant disclosures, and approved indications for use, please refer to the U.S. FDA 510(k) K252361 summary and product labeling.

AccurECG results are not intended to serve as the sole basis for diagnosis. The system is offered to qualified healthcare professionals on an advisory basis only and should be used in conjunction with the physician’s expertise, knowledge of ECG patterns, patient background, clinical history, symptoms, and other diagnostic information.

AK-AVS™ and AK+ Guard™ are currently for research use only and have not been cleared or approved by the US FDA for use in the United States. This technology is under development and intended solely for investigational purposes. It should not be used for clinical diagnosis, treatment, or disease screening at this time. AK-AVS™ and AK+ GuardTM are currently patent pending.

The information provided on this website is for informational purposes only and does not constitute medical, legal, or professional advice. Always consult a qualified healthcare provider for clinical decision-making.